Skip to content
DataLookout
Menu

RISE-1NCT07896265

Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percent change in body weight
Timeframe: From baseline to week 72

Secondary (27)

Change in body weight
Occurrence of ≥5% reduction in body weight
Occurrence of ≥10% reduction in body weight
Occurrence of ≥15% reduction in body weight
Occurrence of ≥20% reduction in body weight
Show 22 moreShow less
Change in waist circumference
Change in Systolic Blood Pressure (SBP)
Change in Diastolic Blood Pressure (DBP)
Change in Hemoglobin A1C (HbA1c)
Change in Fasting Plasma Glucose (FPG)
Percent change in total cholesterol
Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)
Percent change in High-Density Lipoprotein Cholesterol (HDL-C)
Percent change in non-HDL-C
Percent change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C)
Percent change in triglycerides
Percent change in Apolipoprotein B (ApoB)
Percent change in high-sensitivity C-Reactive Protein (hs-CRP)
Percent change in urine Albumin-Creatinine Ratio (uACR)
Change in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Physical Function score
Change in IWQOL-Lite-CT Physical Composite score
Change in IWQOL-Lite-CT Total score
Concentrations of olatorepatide in plasma
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
Magnitude of ADA to olatorepatide
Occurrence of Neutralizing Antibody (NAb) to olatorepatide
Occurrence of Treatment-Emergent Adverse Events (TEAEs)

Arms and interventions

Olatorepatide-Dose 1Experimental
Olatorepatide-Dose 2Experimental
Olatorepatide-Dose 3Experimental
Placebo-Dose 1Placebo comparator
Placebo-Dose 2Placebo comparator

Drugs: Olatorepatide, Placebo